U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S.Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in ...